Sina Kianoush, MD
Cardiovascular Disease · Orange, CANPI 1255867743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,317 of the $3,505 with a category attached, or 66.1%. Abbott accounts for 69.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $2,798 and has fallen 86.0% since, to $391 in 2025.
Across 28 payments — averaging $125.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Heartflow, Inc.$158
- Amgen$142
- Medtronic$129
- Novartis$125
- Novo Nordisk$125
- plus $387 from 7 others
What the payments were for
- Travel & lodging$1,18834%
- Food & beverage$2,31766%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $2,439 |
| Heartflow, Inc. | 3 | $158 |
| Amgen | 2 | $142 |
| Medtronic | 1 | $129 |
| Novartis | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 3 | $87 |
| Cardiva Medical, Inc. | 1 | $86 |
| Regeneron | 1 | $75 |
| AstraZeneca | 1 | $66 |
| Boehringer Ingelheim | 1 | $26 |
| Pfizer | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$1,500
- GALLANT$625
- AMPLATZER TALISMAN$178
- CARDIOMEMS$137
- ENDURANT IIS$129
- LEQVIO$125
- Repatha$125
- Ozempic$125
How this compares
$3,505 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Orange
- Morton KernOrange$314K
- Michael ChanOrange$297K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.